Loading clinical trials...
Loading clinical trials...
The primary efficacy parameter will be the responder rate, defined as the proportion of subjects who had at least a 50% reduction in 28 day seizure rate during the maintenance phase
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
NCT02531880 · Epilepsy
NCT06097195 · Epilepsy
NCT06315322 · Childhood Absence Epilepsy, Juvenile Absence Epilepsy
NCT06388707 · Drug Resistant Epilepsy, Epilepsy, and more
NCT06794606 · Epilepsy
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions